Hologic stock holds steady as investors weigh FDA recall and recent earnings

Published on 09/14/2026 at 22:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hologic stock trades near the mid-70 dollar range as of September 13, 2026, following an FDA Class II recall posted in April 2026. Recent quarterly figures and ongoing regulatory scrutiny keep risk and growth in focus for investors.

Fotorealistisches Mammographiegerät in hellem klinischem Untersuchungsraum mit Pflegekraft — Hologic zeigt ein Mammographie Gerät in einem modernen klinischen Untersuchungsraum ISIN US4364401012, Illustration mit AI erstellt.

Hologic, Inc. stock (ISIN US4364401012) is trading around the mid-70 dollar range on Nasdaq as of September 13, 2026, leaving investors to balance solid earnings with regulatory risk after an FDA Class II recall earlier this year. According to the latest quote data, the shares closed near USD 76, giving the company a multibillion-dollar market capitalization in the medical technology sector.

Regulatory recall frames risk narrative

A key backdrop for Hologic stock in September 2026 is an FDA notice that lists a Class II recall for a Hologic device, posted on April 24, 2026, in the agency's Total Product Life Cycle database for the manufacturer Hologic, Inc. According to the FDA on April 24, 2026, the case is classified as a Class II event, signaling a moderate risk level that nevertheless requires corrective action.

For shareholders, the recall highlights that regulatory oversight remains an important factor alongside earnings performance, especially in diagnostics and imaging businesses where product quality and safety are central to long-term growth. The market has so far treated the incident as manageable rather than a fundamental break, with the stock continuing to trade in the same general range as before the posting date of April 24, 2026.

Earnings support valuation but comparisons matter

Beyond the recall, Hologic's most recent quarterly and fiscal-year results continue to form the foundation of its valuation, with revenue in the latest reported fiscal year reaching several billion dollars and net income in the hundreds of millions, according to the company’s investor relations materials and standard financial portals that summarize the period. The most recently completed fiscal year, which ended within the past 24 months, showed revenue up by a mid-single-digit percentage versus the prior year, while earnings per share grew at a similar pace, indicating steady but not explosive expansion.

On a quarterly basis, the last reported quarter within the past nine months showed revenue increasing by a mid- to high-single-digit percent compared with the same period a year earlier, while adjusted earnings per share also rose by a comparable rate. That combination of revenue and EPS growth versus the prior year gives Hologic some support for its current valuation multiples, even as growth investors often look for double-digit gains in diagnostics and life-science tools names.

Guidance from management for the current fiscal year, as summarized by financial portals referencing Hologic’s latest outlook, points to continued modest revenue growth and disciplined margin management. Compared with historical performance, the current guidance range implies that Hologic expects to hold or slightly expand operating margins, a key metric for investors given the mix of higher-margin assay revenues and more capital-intensive imaging systems.

Analyst views and sector context

In analyst coverage compiled by major financial portals, Hologic stock is generally rated between Hold and Buy, with consensus price targets implying limited but positive upside from the mid-70 dollar share price level as of September 13, 2026. Compared with earlier in the year, the current average target is only a few dollars above prior consensus, highlighting that Wall Street sees incremental rather than dramatic rerating in the near term.

Some houses emphasize that regulatory events such as the April 24, 2026, Class II recall are a reminder that execution risk is inherent in medical device portfolios, while still viewing Hologic’s diversified diagnostics revenue base as a stabilizing factor. In sector roundups of health-care and med-tech names, Hologic is often grouped with other mid- to large-cap diagnostics and imaging companies, with investors watching macroeconomic data and interest rate expectations closely because these affect valuation multiples for growth stocks.

Stock valuation and recent trading levels

As of the last completed trading day on September 13, 2026, Hologic stock traded near USD 76 on Nasdaq, with the share price situated roughly in the middle of its 52-week range between a low in the mid-60 dollar area and a high in the low-80 dollar zone. Based on this price, the company’s market capitalization stands in the multi-billion dollar bracket, reflecting its role as a significant player in diagnostics and medical imaging.